Design and optimization strategies for the development of new drugs that treat chronic kidney disease

References

• Ortiz A, Sanchez-Niño MD, Crespo-Barrio M, et al. The Spanish society of nephrology (SENEFRO) commentary to the Spain GBD 2016 report: keeping chronic kidney disease out of sight of health authorities will only magnify the problem. Nefrologia. 2019;39(1):29–34.
   PubMed Web of Science ®Google Scholar
• Foreman KJ, Marquez N, Dolgert A, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories. Lancet. 2018;392(10159):2052–2090.
   PubMed Web of Science ®Google Scholar
• Perez-Gomez MV, Bartsch LA, Castillo-Rodriguez E, et al. Clarifying the concept of chronic kidney disease for non-nephrologists. Clin Kidney J. 2019;12(2):258–261.
   PubMed Web of Science ®Google Scholar
• Perez-Gomez MV, Martin-Cleary C, Fernandez-Fernandez B, et al. Meso-American nephropathy: what we have learned about the potential genetic influence on chronic kidney disease development. Clin Kidney J. 2018;11(4):491–495.
   PubMed Web of Science ®Google Scholar
• Martín-Cleary C, Ortiz A. CKD hotspots around the world: where, why and what the lessons are. A CKJ review series. . Clin Kidney J. 2014;7(6):519–523.
   PubMedGoogle Scholar
• Association AD. 11. Microvascular complications and foot care. Diabetes Care. 2019;42(Suppl 1):S124–S38.
   PubMedGoogle Scholar
• Perkins RM, Chang AR, Wood KE, et al. Incident chronic kidney disease: trends in management and outcomes. Clin Kidney J. 2016;9(3):432–437.
   PubMed Web of Science ®Google Scholar
• Sanz AB, Ramos AM, Soler MJ, et al. Advances in understanding the role of angiotensin-regulated proteins in kidney diseases. Expert Rev Proteomics. 2019;16(1):77–92.
   Web of Science ®Google Scholar
• Thomson HJ, Ekinci EI, Radcliffe NJ, et al. Elevated baseline glomerular filtration rate (GFR) is independently associated with a more rapid decline in renal function of patients with type 1 diabetes. J Diabetes Complications. 2016;30(2):256–261.
   PubMed Web of Science ®Google Scholar
• Mezzano SA, Ruiz-Ortega M, Egido J. Angiotensin II and renal fibrosis. Hypertension. 2001;38(3 Pt 2):635–638.
   PubMed Web of Science ®Google Scholar
• Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861–869.
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851–860.
   PubMed Web of Science ®Google Scholar
• Fernandez-Fernandez B, Fernandez-Prado R, Górriz JL, et al. Canagliflozin and renal events in diabetes with established nephropathy clinical evaluation and study of diabetic nephropathy with atrasentan: what was learned about the treatment of diabetic kidney disease with canagliflozin and atrasentan? Clin Kidney J. 2019;12(3):313–321.
   PubMed Web of Science ®Google Scholar
• Makani H, Bangalore S, Desouza KA, et al. Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials. BMJ. 2013;346:f360.
   PubMedGoogle Scholar
• Esteras R, Perez-Gomez MV, Rodriguez-Osorio L, et al. Combination use of medicines from two classes of renin-angiotensin system blocking agents: risk of hyperkalemia, hypotension, and impaired renal function. Ther Adv Drug Saf. 2015;6(4):166–176.
   PubMed Web of Science ®Google Scholar
• Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013;369(20):1892–1903.
   PubMed Web of Science ®Google Scholar
• Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (The ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372(9638):547–553.
   PubMed Web of Science ®Google Scholar
• Navaneethan SD, Nigwekar SU, Sehgal AR, et al. Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev. 2014;29(4):CD007004.
   Google Scholar
• Sarafidis P, Ferro CJ, Morales E, et al. SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA. Nephrol Dial Transplant. 2019;34(2):208–230.
   PubMed Web of Science ®Google Scholar
• Cherney DZI, Zinman B, Inzucchi SE, et al. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017;5(8):610–621.
   PubMed Web of Science ®Google Scholar
• Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–657.
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–357.
   PubMed Web of Science ®Google Scholar
• Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–2306.
   PubMed Web of Science ®Google Scholar
• Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669–2701.
   PubMed Web of Science ®Google Scholar
• [cited 2019 Oct 28]. Available from: https://clinicaltrials.gov/.
   Google Scholar
• McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019. [Epub ahead of print].
   Web of Science ®Google Scholar
• Spithoven EM, Kramer A, Meijer E, et al. Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival–an analysis of data from the ERA-EDTA registry. Nephrol Dial Transplant. 2014;29(Suppl 4):iv15–25.
   PubMedGoogle Scholar
• Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet. 2007;369(9569):1287–1301.
   PubMed Web of Science ®Google Scholar
• Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367(25):2407–2418.
   PubMed Web of Science ®Google Scholar
• Blair HA. Tolvaptan: a review in autosomal dominant polycystic kidney disease. Drugs. 2019;79(3):303–313.
   PubMed Web of Science ®Google Scholar
• Center for drug evaluation and research application number: 204441Orig1s000 Labeling. [cited 2019 Oct 28]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/204441Orig1s000Lbl.pdf.
   Google Scholar
• Annex I summary of product characteristics. [cited 2019 Oct 28]. Available from: https://www.ema.europa.eu/en/documents/product-information/jinarc-epar-product-information_en.pdf.
   Google Scholar
• Ortiz A, Germain DP, Desnick RJ, et al. Fabry disease revisited: management and treatment recommendations for adult patients. Mol Genet Metab. 2018;123(4):416–427.
   PubMed Web of Science ®Google Scholar
• El Dib R, Gomaa H, Ortiz A, et al. Enzyme replacement therapy for Anderson-Fabry disease: a complementary overview of a cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies. PLoS One. 2017;12(3):e0173358.
   PubMed Web of Science ®Google Scholar
• Ortiz A, Abiose A, Bichet DG, et al. Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry registry. J Med Genet. 2016;53(7):495–502.
   PubMed Web of Science ®Google Scholar
• Trimarchi H, Canzonieri R, Schiel A, et al. Increased urinary CD80 excretion and podocyturia in Fabry disease. J Transl Med. 2016;14(1):289.
   PubMedGoogle Scholar
• Sanchez-Niño MD, Carpio D, Sanz AB, et al. Lyso-Gb3 activates Notch1 in human podocytes. Hum Mol Genet. 2015;24(20):5720–5732.
   PubMed Web of Science ®Google Scholar
• Weidemann F, Sanchez-Niño MD, Politei J, et al. Fibrosis: a key feature of Fabry disease with potential therapeutic implications. Orphanet J Rare Dis. 2013;8:116.
   PubMed Web of Science ®Google Scholar
• Sanchez-Niño MD, Sanz AB, Carrasco S, et al. Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy. Nephrol Dial Transplant. 2011;26(6):1797–1802.
   PubMed Web of Science ®Google Scholar
• Ortiz A, Sanchez-Niño MD. Enzyme replacement therapy dose and Fabry nephropathy. Nephrol Dial Transplant. 2018;33(8):1284–1289.
   PubMed Web of Science ®Google Scholar
• Natoli TA, Smith LA, Rogers KA, et al. Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models. Nat Med. 2010;16(7):788–792.
   PubMed Web of Science ®Google Scholar
• Perez-Gomez MV, Sanchez-Niño MD, Sanz AB, et al. Targeting inflammation in diabetic kidney disease: early clinical trials. Expert Opin Investig Drugs. 2016;25(9):1045–1058.
   PubMed Web of Science ®Google Scholar
• Heerspink HJL, Parving HH, Andress DL, et al. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet. 2019;393(10184):1937–1947.
   PubMed Web of Science ®Google Scholar
• Navarro-González JF, Sánchez-Niño MD, Donate-Correa J, et al. Effects of pentoxifylline on soluble klotho concentrations and renal tubular cell expression in diabetic kidney disease. Diabetes Care. 2018;41(8):1817–1820.
   PubMed Web of Science ®Google Scholar
• de Zeeuw D, Renfurm RW, Bakris G, et al. Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2018;6(12):925–933.
   PubMed Web of Science ®Google Scholar
• Bakris GL, Agarwal R, Chan JC, et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA. 2015;314(9):884–894.
   PubMed Web of Science ®Google Scholar
• Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–1844.
   PubMed Web of Science ®Google Scholar
• Mann JFE, Ørsted DD, Brown-Frandsen K, et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med. 2017;377(9):839–848.
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247–2257.
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121–130.
   PubMed Web of Science ®Google Scholar
• Cuarental L, Sucunza-Sáenz D, Valiño-Rivas L, et al. MAP3K kinases and kidney injury. Nefrologia. 2019;39:568–580. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Webster AC, Nagler EV, Morton RL, et al. Chronic kidney disease. Lancet. 2017;389(10075):1238–1252.
   PubMed Web of Science ®Google Scholar
• Hartono C, Chung M, Perlman AS, et al. Bortezomib for reduction of proteinuria in IgA nephropathy. Kidney Int Rep. 2018;3(4):861–866.
   PubMed Web of Science ®Google Scholar
• Bomback AS, Fervenza FC. Membranous nephropathy: approaches to treatment. Am J Nephrol. 2018;47(Suppl 1):30–42.
   PubMedGoogle Scholar
• Ruggenenti P, Fervenza FC, Remuzzi G. Treatment of membranous nephropathy: time for a paradigm shift. Nat Rev Nephrol. 2017;13(9):563–579.
   PubMed Web of Science ®Google Scholar
• Hartono C, Chung M, Kuo SF, et al. Bortezomib therapy for nephrotic syndrome due to idiopathic membranous nephropathy. J Nephrol. 2014;27(1):103–106.
   PubMed Web of Science ®Google Scholar
• Fervenza FC, Appel GB, Barbour SJ, et al. Rituximab or cyclosporine in the treatment of membranous nephropathy. N Engl J Med. 2019;381(1):36–46.
   PubMed Web of Science ®Google Scholar
• Barrett C, Willcocks LC, Jones RB, et al. Effect of belimumab on proteinuria and anti-phospholipase A2 receptor autoantibody in primary membranous nephropathy. Nephrol Dial Transplant. 2019. [Epub ahead of print].
   PubMedGoogle Scholar
• Komers R, Gipson DS, Nelson P, et al. Efficacy and safety of sparsentan compared with irbesartan in patients with primary focal segmental glomerulosclerosis: randomized, controlled trial design (DUET). Kidney Int Rep. 2017;2(4):654–664.
   PubMed Web of Science ®Google Scholar
• Trachtman H, Nelson P, Adler S, et al. DUET: a phase 2 study evaluating the efficacy and safety of sparsentan in patients with FSGS. J Am Soc Nephrol. 2018;29(11):2745–2754.
   PubMed Web of Science ®Google Scholar
• Weimbs T, Shillingford JM, Torres J, et al. Emerging targeted strategies for the treatment of autosomal dominant polycystic kidney disease. Clin Kidney J. 2018;11(Suppl 1):i27–i38.
   PubMedGoogle Scholar
• Toto RD. Bardoxolone-the phoenix? J Am Soc Nephrol. 2018;29(2):360–361.
   PubMed Web of Science ®Google Scholar
• Sweeney WE, Frost P, Avner ED. Tesevatinib ameliorates progression of polycystic kidney disease in rodent models of autosomal recessive polycystic kidney disease. World J Nephrol. 2017;6(4):188–200.
   PubMedGoogle Scholar
• Müller RU, Benzing T. Management of autosomal-dominant polycystic kidney disease-state-of-the-art. Clin Kidney J. 2018;11(Suppl 1):i2–i13.
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Hashimoto R, Xie H, et al. Growth and antibiotic resistance acquisition of escherichia coli in a river that receives treated sewage effluent. Sci Total Environ. 2019;690:696–704.
   PubMed Web of Science ®Google Scholar
• Franceschi C, Bonafè M. Centenarians as a model for healthy aging. Biochem Soc Trans. 2003;31(2):457–461.
   PubMed Web of Science ®Google Scholar
• Valentijn FA, Falke LL, Nguyen TQ, et al. Cellular senescence in the aging and diseased kidney. J Cell Commun Signal. 2018;12(1):69–82.
   PubMed Web of Science ®Google Scholar
• Coppé JP, Patil CK, Rodier F, et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 2008;6(12):2853–2868.
   PubMed Web of Science ®Google Scholar
• Coppé JP, Desprez PY, Krtolica A, et al. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol. 2010;5:99–118.
   PubMed Web of Science ®Google Scholar
• Sturmlechner I, Durik M, Sieben CJ, et al. Cellular senescence in renal ageing and disease. Nat Rev Nephrol. 2017;13(2):77–89.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Tchkonia T, Pirtskhalava T, et al. The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell. 2015;14(4):644–658.
   PubMed Web of Science ®Google Scholar
• Baar MP, Brandt RMC, Putavet DA, et al. Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging. Cell. 2017;169(1):132–47.e16.
   PubMed Web of Science ®Google Scholar
• Palmer AK, Xu M, Zhu Y, et al. Targeting senescent cells alleviates obesity-induced metabolic dysfunction. Aging Cell. 2019;18(3):e12950.
   PubMed Web of Science ®Google Scholar
• Baker DJ, Childs BG, Durik M, et al. Naturally occurring p16(Ink4a)-positive cells shorten healthy lifespan. Nature. 2016;530(7589):184–189.
   PubMed Web of Science ®Google Scholar
• Jin H, Zhang Y, Ding Q, et al. Epithelial innate immunity mediates tubular cell senescence after kidney injury. JCI Insight. 2019;4(2).
   Web of Science ®Google Scholar
• Castellano G, Franzin R, Sallustio F, et al. Complement component C5a induces aberrant epigenetic modifications in renal tubular epithelial cells accelerating senescence by Wnt4/βcatenin signaling after ischemia/reperfusion injury. Aging (Albany NY). 2019;11(13):4382–4406.
   PubMedGoogle Scholar
• Chen SF, Chen M. Complement activation in progression of chronic kidney disease. Adv Exp Med Biol. 2019;1165:423–441.
   PubMed Web of Science ®Google Scholar
• Ricklin D, Mastellos DC, Reis ES, et al. The renaissance of complement therapeutics. Nat Rev Nephrol. 2018;14(1):26–47.
   PubMed Web of Science ®Google Scholar
• Kassimatis T, Qasem A, Douiri A, et al. A double-blind randomised controlled investigation into the efficacy of Mirococept (APT070) for preventing ischaemia reperfusion injury in the kidney allograft (EMPIRIKAL): study protocol for a randomised controlled trial. Trials. 2017;18(1):255.
   PubMedGoogle Scholar
• Lee JW, Sicre de Fontbrune F, Wong Lee Lee L, et al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood. 2019;133(6):530–539.
   PubMed Web of Science ®Google Scholar
• Kulasekararaj AG, Hill A, Rottinghaus ST, et al. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. Blood. 2019;133(6):540–549.
   PubMed Web of Science ®Google Scholar
• Jayne DRW, Bruchfeld AN, Harper L, et al. Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis. J Am Soc Nephrol. 2017;28(9):2756–2767.
   PubMed Web of Science ®Google Scholar
• Izquierdo MC, Perez-Gomez MV, Sanchez-Niño MD, et al. Klotho, phosphate and inflammation/ageing in chronic kidney disease. Nephrol Dial Transplant. 2012;27(Suppl 4):iv6–10.
   PubMedGoogle Scholar
• Fernandez-Fernandez B, Izquierdo MC, Valiño-Rivas L, et al. Albumin downregulates Klotho in tubular cells. Nephrol Dial Transplant. 2018;33(10):1712–1722.
   PubMed Web of Science ®Google Scholar
• Moreno JA, Izquierdo MC, Sanchez-Niño MD, et al. The inflammatory cytokines TWEAK and TNFα reduce renal klotho expression through NFκB. J Am Soc Nephrol. 2011;22(7):1315–1325.
   PubMed Web of Science ®Google Scholar
• Poveda J, Sanz AB, Rayego-Mateos S, et al. NFκBiz protein downregulation in acute kidney injury: modulation of inflammation and survival in tubular cells. Biochim Biophys Acta. 2016;1862(4):635–646.
   PubMed Web of Science ®Google Scholar
• Martin-Sanchez D, Ruiz-Andres O, Poveda J, et al. Ferroptosis, but not necroptosis, is important in nephrotoxic folic acid-induced AKI. J Am Soc Nephrol. 2017;28(1):218–229.
   PubMed Web of Science ®Google Scholar
• Poveda J, Sanz AB, Carrasco S, et al. Bcl3: a regulator of NF-κB inducible by TWEAK in acute kidney injury with anti-inflammatory and antiapoptotic properties in tubular cells. Exp Mol Med. 2017;49(7):e352.
   PubMedGoogle Scholar
• Valiño-Rivas L, Cuarental L, Nuñez G, et al. Loss of NLRP6 expression increases the severity of acute kidney injury. Nephrol Dial Transplant. 2019. [Epub ahead of print].
   Web of Science ®Google Scholar
• Castellano G, Intini A, Stasi A, et al. Complement modulation of anti-aging factor Klotho in ischemia/reperfusion injury and delayed graft function. Am J Transplant. 2016;16(1):325–333.
   PubMed Web of Science ®Google Scholar
• Castillo-Rodriguez E, Fernandez-Prado R, Esteras R, et al. Impact of altered intestinal microbiota on chronic kidney disease progression. Toxins (Basel). 2018;10(7):300.
   Web of Science ®Google Scholar
• Tsai YL, Lin TL, Chang CJ, et al. Probiotics, prebiotics and amelioration of diseases. J Biomed Sci. 2019;26(1):3.
   PubMedGoogle Scholar
• Asai M, Kumakura S, Kikuchi M. Review of the efficacy of AST-120 (KREMEZIN. Ren Fail. 2019;41(1):47–56.
   PubMed Web of Science ®Google Scholar
• Desrochers TM, Palma E, Kaplan DL. Tissue-engineered kidney disease models. Adv Drug Deliv Rev. 2014;69–70:67–80.
   PubMed Web of Science ®Google Scholar
• Poosti F, Pham BT, Oosterhuis D, et al. Precision-cut kidney slices (PCKS) to study development of renal fibrosis and efficacy of drug targeting ex vivo. Dis Model Mech. 2015;8(10):1227–1236.
   PubMed Web of Science ®Google Scholar
• Benedetti V, Brizi V, Guida P, et al. Engineered kidney tubules for modeling patient-specific diseases and drug discovery. EBioMedicine. 2018;33:253–268.
   PubMed Web of Science ®Google Scholar
• Qu Y, An F, Luo Y, et al. A nephron model for study of drug-induced acute kidney injury and assessment of drug-induced nephrotoxicity. Biomaterials. 2018;155:41–53.
   PubMed Web of Science ®Google Scholar
• Bukanov NO, Moreno SE, Natoli TA, et al. CDK inhibitors R-roscovitine and S-CR8 effectively block renal and hepatic cystogenesis in an orthologous model of ADPKD. Cell Cycle. 2012;11(21):4040–4046.
   PubMed Web of Science ®Google Scholar
• Zhou H, Gao J, Zhou L, et al. Ginkgolide B inhibits renal cyst development in in vitro and in vivo cyst models. Am J Physiol Renal Physiol. 2012;302(10):F1234–42.
   PubMed Web of Science ®Google Scholar
• Takiar V, Nishio S, Seo-Mayer P, et al. Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis. Proc Natl Acad Sci U S A. 2011;108(6):2462–2467.
   PubMed Web of Science ®Google Scholar
• Yamaguchi T, Reif GA, Calvet JP, et al. Sorafenib inhibits cAMP-dependent ERK activation, cell proliferation, and in vitro cyst growth of human ADPKD cyst epithelial cells. Am J Physiol Renal Physiol. 2010;299(5):F944–51.
   PubMed Web of Science ®Google Scholar
• Reif GA, Yamaguchi T, Nivens E, et al. Tolvaptan inhibits ERK-dependent cell proliferation, Cl⁻ secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin. Am J Physiol Renal Physiol. 2011;301(5):F1005–13.
   PubMed Web of Science ®Google Scholar
• Moll S, Ebeling M, Weibel F, et al. Epithelial cells as active player in fibrosis: findings from an in vitro model. PLoS One. 2013;8(2):e56575.
   PubMed Web of Science ®Google Scholar
• Ortiz A, Sanchez-Niño MD, Izquierdo MC, et al. Translational value of animal models of kidney failure. Eur J Pharmacol. 2015;759:205–220.
   PubMed Web of Science ®Google Scholar
• Aihara M, Fujiki H, Mizuguchi H, et al. Tolvaptan delays the onset of end-stage renal disease in a polycystic kidney disease model by suppressing increases in kidney volume and renal injury. J Pharmacol Exp Ther. 2014;349(2):258–267.
   PubMed Web of Science ®Google Scholar
• de Jorge EG, Macor P, Paixão-Cavalcante D, et al. The development of atypical hemolytic uremic syndrome depends on complement C5. J Am Soc Nephrol. 2011;22(1):137–145.
   PubMed Web of Science ®Google Scholar
• Daehn I, Casalena G, Zhang T, et al. Endothelial mitochondrial oxidative stress determines podocyte depletion in segmental glomerulosclerosis. J Clin Invest. 2014;124(4):1608–1621.
   PubMed Web of Science ®Google Scholar
• Heymann F, Meyer-Schwesinger C, Hamilton-Williams EE, et al. Kidney dendritic cell activation is required for progression of renal disease in a mouse model of glomerular injury. J Clin Invest. 2009;119(5):1286–1297.
   PubMed Web of Science ®Google Scholar
• Shi S, Yu L, Chiu C, et al. Podocyte-selective deletion of dicer induces proteinuria and glomerulosclerosis. J Am Soc Nephrol. 2008;19(11):2159–2169.
   PubMed Web of Science ®Google Scholar
• Traykova-Brauch M, Schönig K, Greiner O, et al. An efficient and versatile system for acute and chronic modulation of renal tubular function in transgenic mice. Nat Med. 2008;14(9):979–984.
   PubMed Web of Science ®Google Scholar
• Kramann R, Fleig SV, Schneider RK, et al. Pharmacological GLI2 inhibition prevents myofibroblast cell-cycle progression and reduces kidney fibrosis. J Clin Invest. 2015;125(8):2935–2951.
   PubMed Web of Science ®Google Scholar
• Zhou D, Fu H, Zhang L, et al. Tubule-derived wnts are required for fibroblast activation and kidney fibrosis. J Am Soc Nephrol. 2017;28(8):2322–2336.
   PubMed Web of Science ®Google Scholar
• Zhou L, Chen X, Lu M, et al. Wnt/β-catenin links oxidative stress to podocyte injury and proteinuria. Kidney Int. 2019;95(4):830–845.
   PubMed Web of Science ®Google Scholar
• MacRae CA, Peterson RT. Zebrafish as tools for drug discovery. Nat Rev Drug Discov. 2015;14(10):721–731.
   PubMed Web of Science ®Google Scholar
• Gehrig J, Pandey G, Westhoff JH. Zebrafish as a model for drug screening in genetic kidney diseases. Front Pediatr. 2018;6:183.
   PubMed Web of Science ®Google Scholar
• Sanchez-Niño MD, Sanz AB, Ihalmo P, et al. The MIF receptor CD74 in diabetic podocyte injury. J Am Soc Nephrol. 2009;20(2):353–362.
   PubMed Web of Science ®Google Scholar
• Valiño-Rivas L, Cuarental L, Grana O, et al. TWEAK increases CD74 expression and sensitizes to DDT proinflammatory actions in tubular cells. PLoS One. 2018;13(6):e0199391.
   PubMed Web of Science ®Google Scholar
• Li J, Tang Y, Tang PMK, et al. Blocking macrophage migration inhibitory factor protects against cisplatin-induced acute kidney injury in mice. Mol Ther. 2018;26(10):2523–2532.
   PubMed Web of Science ®Google Scholar
• Ochi A, Chen D, Schulte W, et al. MIF-2/D-DT enhances proximal tubular cell regeneration through SLPI- and ATF4-dependent mechanisms. Am J Physiol Renal Physiol. 2017;313(3):F767–F80.
   PubMed Web of Science ®Google Scholar
• Sanchez-Niño MD, Sanz AB, Lorz C, et al. BASP1 promotes apoptosis in diabetic nephropathy. J Am Soc Nephrol. 2010;21(4):610–621.
   PubMed Web of Science ®Google Scholar
• Sanchez-Niño MD, Fernandez-Fernandez B, Perez-Gomez MV, et al. Albumin-induced apoptosis of tubular cells is modulated by BASP1. Cell Death Dis. 2015;6:e1644.
   PubMed Web of Science ®Google Scholar
• Ortiz A, Husi H, Gonzalez-Lafuente L, et al. Mitogen-activated protein kinase 14 promotes AKI. J Am Soc Nephrol. 2017;28(3):823–836.
   PubMed Web of Science ®Google Scholar
• Panchapakesan U, Pollock C. Drug repurposing in kidney disease. Kidney Int. 2018;94(1):40–48.
   PubMed Web of Science ®Google Scholar
• Li J, Zheng S, Chen B, et al. A survey of current trends in computational drug repositioning. Brief Bioinform. 2016;17(1):2–12.
   PubMed Web of Science ®Google Scholar
• Sanchez GAM, Reinhardt A, Ramsey S, et al. JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. J Clin Invest. 2018;128(7):3041–3052.
   PubMed Web of Science ®Google Scholar
• Wallace DJ, Furie RA, Tanaka Y, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2018;392(10143):222–231.
   PubMed Web of Science ®Google Scholar
• Tuttle KR, Brosius FC, Adler SG, et al. JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a phase 2 randomized controlled clinical trial. Nephrol Dial Transplant. 2018;33(11):1950–1959.
   PubMed Web of Science ®Google Scholar
• Carducci MA, Padley RJ, Breul J, et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol. 2003;21(4):679–689.
   PubMed Web of Science ®Google Scholar
• Kassab S, Miller MT, Novak J, et al. Endothelin-A receptor antagonism attenuates the hypertension and renal injury in dahl salt-sensitive rats. Hypertension. 1998;31(1 Pt 2):397–402.
   PubMed Web of Science ®Google Scholar
• von Mässenhausen A, Tonnus W, Himmerkus N, et al. Phenytoin inhibits necroptosis. Cell Death Dis. 2018;9(3):359.
   PubMedGoogle Scholar
• Martin-Sanchez D, Fontecha-Barriuso M, Carrasco S, et al. TWEAK and RIPK1 mediate a second wave of cell death during AKI. Proc Natl Acad Sci U S A. 2018;115(16):4182–4187.
   PubMed Web of Science ®Google Scholar
• Duncan R, Vicent MJ. Polymer therapeutics-prospects for 21st century: the end of the beginning. Adv Drug Deliv Rev. 2013;65(1):60–70.
   PubMed Web of Science ®Google Scholar
• Atkinson SP, Andreu Z, Vicent MJ. Polymer therapeutics: biomarkers and new approaches for personalized cancer treatment. J Pers Med. 2018;8(1):6.
   PubMed Web of Science ®Google Scholar
• Kamada H, Tsutsumi Y, Sato-Kamada K, et al. Synthesis of a poly(vinylpyrrolidone-co-dimethyl maleic anhydride) co-polymer and its application for renal drug targeting. Nat Biotechnol. 2003;21(4):399–404.
   PubMed Web of Science ®Google Scholar
• Yuan ZX, Sun X, Gong T, et al. Randomly 50% N-acetylated low molecular weight chitosan as a novel renal targeting carrier. J Drug Target. 2007;15(4):269–278.
   PubMed Web of Science ®Google Scholar
• Qiao H, Sun M, Su Z, et al. Kidney-specific drug delivery system for renal fibrosis based on coordination-driven assembly of catechol-derived chitosan. Biomaterials. 2014;35(25):7157–7171.
   PubMed Web of Science ®Google Scholar
• Li J, Zhang C, He W, et al. Coordination-driven assembly of catechol-modified chitosan for the kidney-specific delivery of salvianolic acid B to treat renal fibrosis. Biomater Sci. 2017;6(1):179–188.
   PubMed Web of Science ®Google Scholar
• Chai HJ, Kiew LV, Chin Y, et al. Renal targeting potential of a polymeric drug carrier, poly-l-glutamic acid, in normal and diabetic rats. Int J Nanomedicine. 2017;12:577–591.
   PubMed Web of Science ®Google Scholar
• Ucero AC, Berzal S, Ocaña-Salceda C, et al. A polymeric nanomedicine diminishes inflammatory events in renal tubular cells. PLoS One. 2013;8(1):e51992.
   PubMed Web of Science ®Google Scholar
• Duro-Castano A, England RM, Razola D, et al. Well-defined star-shaped polyglutamates with improved pharmacokinetic profiles as excellent candidates for biomedical applications. Mol Pharm. 2015;12(10):3639–3649.
   PubMedGoogle Scholar
• Duro-Castano A, Nebot VJ, Niño-Pariente A, et al. Capturing “Extraordinary” soft-assembled charge-like polypeptides as a strategy for nanocarrier design. Adv Mater. 2017;29(39).
   PubMed Web of Science ®Google Scholar
• Scindia Y, Deshmukh U, Thimmalapura PR, et al. Anti-alpha8 integrin immunoliposomes in glomeruli of lupus-susceptible mice: a novel system for delivery of therapeutic agents to the renal glomerulus in systemic lupus erythematosus. Arthritis Rheum. 2008;58(12):3884–3891.
   PubMedGoogle Scholar
• Asgeirsdóttir SA, Zwiers PJ, Morselt HW, et al. Inhibition of proinflammatory genes in anti-GBM glomerulonephritis by targeted dexamethasone-loaded AbEsel liposomes. Am J Physiol Renal Physiol. 2008;294(3):F554–61.
   PubMed Web of Science ®Google Scholar
• Suana AJ, Tuffin G, Frey BM, et al. Single application of low-dose mycophenolate mofetil-OX7-immunoliposomes ameliorates experimental mesangial proliferative glomerulonephritis. J Pharmacol Exp Ther. 2011;337(2):411–422.
   PubMed Web of Science ®Google Scholar
• Levin AA. Treating DISEASE at the RNA level with oligonucleotides. N Engl J Med. 2019;380(1):57–70.
   PubMed Web of Science ®Google Scholar
• Chery J. RNA therapeutics: rNAi and antisense mechanisms and clinical applications. Postdoc J. 2016;4(7):35–50.
   PubMedGoogle Scholar
• Bennett CF, Baker BF, Pham N, et al. Pharmacology of antisense drugs. Annu Rev Pharmacol Toxicol. 2017;57:81–105.
   PubMed Web of Science ®Google Scholar
• Singaravelu K, Padanilam BJ. p53 target Siva regulates apoptosis in ischemic kidneys. Am J Physiol Renal Physiol. 2011;300(5):F1130–41.
   PubMed Web of Science ®Google Scholar
• Kluve-Beckerman B, Hardwick J, Du L, et al. Antisense oligonucleotide suppression of serum amyloid A reduces amyloid deposition in mice with AA amyloidosis. Amyloid. 2011;18(3):136–146.
   PubMed Web of Science ®Google Scholar
• Sanchez-Niño MD, Ortiz A. HCV infection and miravirsen. N Engl J Med. 2013;369(9):877–878.
   PubMed Web of Science ®Google Scholar
• Mathew V, Wang AK. Inotersen: new promise for the treatment of hereditary transthyretin amyloidosis. Drug Des Devel Ther. 2019;13:1515–1525.
   PubMed Web of Science ®Google Scholar
• Crooke ST, Baker BF, Pham NC, et al. The effects of 2ʹ-O-methoxyethyl oligonucleotides on renal function in humans. Nucleic Acid Ther. 2018;28(1):10–22.
   PubMed Web of Science ®Google Scholar
• Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391(6669):806–811.
   PubMed Web of Science ®Google Scholar
• Wakefield CE, Doolan EL, Fardell JE, et al. The avatar acceptability study: survivor, parent and community willingness to use patient-derived xenografts to personalize cancer care. EBioMedicine. 2018;37:205–213.
   PubMed Web of Science ®Google Scholar
• Lenders M, Stappers F, Niemietz C, et al. Mutation-specific Fabry disease patient-derived cell model to evaluate the amenability to chaperone therapy. J Med Genet. 2019;56:548–556. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Falke LL, Gholizadeh S, Goldschmeding R, et al. Diverse origins of the myofibroblast—implications for kidney fibrosis. Nat Rev Nephrol. 2015;11(4):233–244.
   PubMed Web of Science ®Google Scholar
• Adams D, Gonzalez-Duarte A, O’Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11–21.
   PubMed Web of Science ®Google Scholar
• FDA Facilitates the Use of Surrogate Endpoints in Drug Development. 2018 Nov 5. Issue. [cited 2019 Oct 28]. Available from: https://www.fda.gov/drugs/fda-facilitates-use-surrogate-endpoints-drug-development-november-5-2018-issue.
   Google Scholar